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Abstract
Background: Smoking cessation following lung cancer diagnosis has been found to improve several patient
outcomes. Electronic cigarette (e-cigarette) use is now prevalent within Great Britain, however, use and practice
among patients with lung cancer has not as yet been explored. The current study aims to explore e-cigarette use
among patients and examine current practice among clinicians. The results have important implications for future
policy and practice.
Methods: Members of The British Thoracic Oncology Group (BTOG) were contacted via several e-circulations
(N = 2,009), requesting them to complete an online survey. Of these, 7.7 % (N = 154) completed the survey, which
explored participant demographics and smoking history, perceptions of patient e-cigarette use, practitioner
knowledge regarding sources of guidance pertaining to e-cigarettes, and practitioner advice.
Results: Practitioners frequently observed e-cigarette use among patients with lung cancer. The majority of
practitioners (81.4 %) reported responding to patient queries pertaining to e-cigarettes within the past year;
however, far fewer (21.0 %) felt confident providing patients with e-cigarette advice. Practitioner confidence
was found to differentiate by gender (p = 0.012) and employment speciality (p = 0.030), with nurses reporting
particularly low levels of confidence in advising. The results also demonstrate extensive variability regarding the
practitioner advice content.
Conclusions: The results demonstrate that patients refer to practitioners as a source of e-cigarette guidance,
yet few practitioners feel confident advising. The absence of evidence-based guidance may have contributed
towards the exhibited inconsistencies in practitioner advice. The findings highlight that training should be
delivered to equip practitioners with the knowledge and confidence to advise patients effectively; this could
subsequently improve smoking cessation rates and patient outcomes.
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Background
In 2012, it was estimated there were 1.8 million new lung
cancer cases and 1.6 million lung cancer deaths worldwide
[1]. Smoking cessation has been identified as one of the
most effective strategies to reduce lung cancer incidence
[2]. Furthermore, smoking cessation has been found to be
highly beneficial among those diagnosed with lung cancer,
as continued tobacco smoking following diagnosis has
been associated with risk of all-cause mortality, cancer re-
currence, and development of a secondary tumour [3].
A recent review highlighted the efficacy of combining
pharmacotherapy, such as varenicline, with cognitive and
behavioural interventions for smoking cessation among
smokers with lung cancer [4]. In the UK, the National In-
stitute for Health and Care Excellence (NICE) produce
guidance regarding the diagnosis and treatment of lung
cancer, in which they recommend practitioners inform
patients of the harms of continuing to smoke tobacco and
urge practitioners to advise patients to stop smoking as
soon as possible, whilst offering pharmacotherapy [5].
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Despite this, 39 % of lung cancer patients are classified as
current smokers at diagnosis and 37 % of these patients
continue to smoke five months following diagnosis [6],
highlighting the importance of exploring attitudes and
perceptions of smoking cessation.
To date, NICE fails to provide guidance regarding the
use of electronic cigarettes (e-cigarettes) among patients
with lung cancer [5] and there is a lack of research in
this context. One recent study conducted in the USA,
reported e-cigarette use among smokers with lung can-
cer to be 24 % within the prior 30 days at the point of
assessment [7], yet e-cigarette use among patients with
lung cancer in Great Britain is currently unclear. The
present study partially aims to ascertain observed patient
use of e-cigarettes. This is important to inform future
policies, research and training offered to practitioners.
A recent review of evidence commissioned by Public
Health England suggests that e-cigarettes are approxi-
mately 95 % less harmful than regular cigarettes and rec-
ommends encouraging smokers struggling to quit, to try
e-cigarettes [8], whilst some researchers have expressed
concerns regarding uptake of e-cigarettes among people
who don’t smoke and about their long term health effect
[9]. Furthermore, from May 2016, it will be necessary for
e-cigarettes to be licenced within the UK by the Medi-
cines and Healthcare products Regulatory Agency
(MHRA) [10], with the aim of improving product safety
and efficacy. In relation to e-cigarette use among lung
cancer patients, The International Association for the
Study of Lung Cancer (IASLC) issued a recent statement
[11], in which they recommend that e-cigarette use
among lung cancer patients is discouraged, due to the
paucity of research pertaining to e-cigarette safety and
efficacy.
In light of the absence of evidence-based guidance
pertaining to e-cigarette use among patients with lung
cancer, this study aimed to explore whether practi-
tioners are aware of the IASLC guidance and in
addition, this study examined the prevalence of work-
based practitioner guidance on the use of e-cigarettes.
This is important to determine, in order to ensure that
practitioners are following current guidance and keep-
ing abreast of any research and policy developments, as
well as enabling the identification of training needs.
Furthermore, the current study aimed to explore the
content of the advice that practitioners were providing
to patients and to establish whether practitioners were
maintaining an evidence-based approach to smoking
cessation.
The current study addresses the following questions:
1) How many cancer patients have asked questions
about e-cigarettes, have tried them, or report
currently using them?
2) Are practitioners aware of sources of e-cigarette
guidance (e.g., IASLC guidance)?
3) Are health services in which practitioners are based
issuing practitioner guidance regarding e-cigarette
use among cancer patients?
4) What advice are practitioners providing to cancer
patients regarding e-cigarettes?
5) Do practitioners identify a need for further guidance
and support with regards to providing patients with
e-cigarette advice and which groups may benefit
from further training?
Methods
Participants
The British Thoracic Oncology Group (BTOG) repre-
sents all disciplines involved in the care of lung cancer
and mesothelioma throughout the UK and includes
medical and clinical oncologists, respiratory physicians,
surgeons, radiotherapists, radiologists, nurses, pharma-
cists and scientists [12]. Two thousand and nine mem-
bers of BTOG were contacted, of which 7.7 % (N = 154)
participants completed the online survey. Of these respon-
dents, seven were excluded as they failed to complete the
survey in full; the finalised study sample consisted of 147
BTOG members.
Table 1 demonstrates that the majority of respondents
were female (n = 95, 64.6 %), between the age range of
30-49 years (n = 89, 60.5 %), never smokers (n = 103,
70.1 %), and never e-cigarette users (n = 132, 90.4 %).
Furthermore, nursing was the most frequently cited line
of employment (n = 52, 35.4 %).
Procedure
Four BTOG e-circulations were posted to 2,009 BTOG
members throughout April and May 2015, in which the
online survey was detailed and members were requested
to participate. The online survey was open between April
1st 2015 and May 31st 2015. Members were provided with
a web-link, which directed them to a participant informa-
tion sheet, consent form, the online questionnaire, and
subsequently, a debrief form, in which participants were
directed to a link to the IASLC statement regarding e-
cigarette use among cancer patients [11].
Measures
All participants were asked several questions pertain-
ing to socio-demographics, smoking history and e-
cigarette use and risk perception. Gender and age were
firstly ascertained. Employment speciality was assessed
based on the categories presented on the membership
page of the BTOG website: [13] “Please describe your
speciality” (Clinical oncology, Clinical trials, Lecturer/
educator, Medical oncology, Nursing, Pharmacy, Pallia-
tive care, Pathology, Radiology, Respiratory, Research/
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science, Surgery, Other). Smoking status was ascertained
using measures from the Behavioral Risk Factor Surveil-
lance System: [14] These measures included: “Have you
smoked at least 100 cigarettes in your entire life?” (Yes,
No) and “Do you now smoke cigarettes every day, some
days, or not at all?” (Every day, Some days, Not at all). The
variable was subsequently collapsed to categorise ever and
never smokers. E-cigarette ever-use was also ascertained,
using a measure adopted in previous studies: [15–17]
“Have you ever tried an electronic cigarette?” (Yes, No).
E-cigarette risk perception was assessed by adapting and
utilising a measure applied in previous research: [18–20]
“Do you think that electronic cigarettes are more harmful
than regular cigarettes, less harmful, or are they equally
harmful to health?” (More harmful than regular cigarettes,
Equally harmful to regular cigarettes, Less harmful than
regular cigarettes, Don’t know). Lastly, patient contact was
established, in order to assess participant suitability for
additional patient-related measures: “In your profession,
do you have contact with patients?” (Yes, I have patient
contact, No, I do not have patient contact).
Participants who reported patient contact were asked a
further three questions pertaining to observed e-cigarette
use among patients, which were adapted from similar
measures of observed e-cigarette use among Stop Smok-
ing Service users: [21, 22] (1) “What proportion of patients
who are current and former smokers you have seen in the
past year have asked you questions about electronic ciga-
rettes (e-cigarettes)?”; (2) “What proportion of patients
who are current and former smokers you have seen in the
past year say they have ever used e-cigarettes?”; (3) “What
proportion of patients who are current and former
smokers you have seen in the past year say they regularly
use e-cigarettes?”. The response options to each of these
three questions, included “None”, “Less than a quarter”,
“From a quarter to a half”, “From a half to three quarters”,
and “More than three quarters”.
Participants were asked five further questions, regarding
sources of e-cigarette guidance, content of advice provided
to patients, and practitioner confidence in advising pa-
tients regarding e-cigarettes. The majority of these ques-
tions were informed by previous research: [21, 22] Does
your workplace have a recommendation of what advice
you should give patients on electronic cigarettes? (Yes,
No); What advice do you give patients about e-
cigarettes? (Open text box of 500 characters); To what
extent do you agree with the following statement: “I
feel I need more information and guidance regarding
electronic cigarettes” (Strongly agree, Agree, Neutral,
Disagree, Strongly disagree). The remaining two ques-
tions were developed by the research group, which con-
sisted of professionals with clinical and research
expertise in the fields of lung cancer and e-cigarettes.
These final questions included: Are you aware of the
statement The International Association for the Study of
Lung Cancer (IASLC) released regarding electronic ciga-
rettes and cancer patients? (Yes, No), and; To what extent
do you agree with the following statement: “I feel
confident advising patients regarding electronic cigarettes”
(Strongly agree, Agree, Neutral, Disagree, Strongly dis-
agree). The aforementioned variable levels for the measure
which explored practitioner confidence advising patients
regarding e-cigarettes were refined prior to bivariate
analyses, due to low cell frequencies; “Strongly agree”
and “Agree” were combined to form “Agree”, “Neutral”
remained the same, and “Strongly Disagree” and “Dis-
agree” were combined to form “Disagree”.
Table 1 Sample characteristics and attitudes towards e-cigarettes
among BTOG members overall
Variable Participants n (%)
Age
18-29 5 (3.4)
30-49 89 (60.5)
50-69 50 (34.0)
70 or above 3 (2.0)
Gender
Female 95 (64.6)
Male 52 (35.4)
Employment field
Clinical oncology 26 (17.7)
Clinical trials 4 (2.7)
Lecturer/educator 1 (0.7)
Medical oncology 11 (7.5)
Nursing 52 (35.4)
Palliative care 1 (0.7)
Pathology 1 (0.7)
Respiratory 31 (21.1)
Research/science 4 (2.7)
Surgery 10 (6.8)
Other 6 (4.1)
Smoking status
Never 103 (70.1)
Ever 44 (29.9)
E-cigarette usea
Never 132 (90.4)
Ever 14 (9.6)
Perceived e-cigarette harma
More harmful than regular cigarettes 3 (2.1)
Equally harmful to regular cigarettes 14 (9.6)
Less harmful than regular cigarettes 100 (68.5)
Don’t know 29 (19.9)
aFigures do not equate to 147 due to some missing data
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Ethical approval
The University of Liverpool provided full ethical ap-
proval for the study (Reference: RETH000832); all par-
ticipants provided informed consent, were made aware
that they could withdraw from the study at any time,
data was anonymised, strict confidentiality guidelines
were adhered to, and participants were aware that the
results derived from the data may be published in a sci-
entific journal. Furthermore, upon submission of the
online questionnaire, participants were directed to a
link to the IASLC statement regarding e-cigarette use
among cancer patients [11].
Data analysis
As described, the study primarily aimed to explore per-
ceived prevalence of e-cigarette use among patients, whilst
considering practitioners’ knowledge regarding sources of
guidance pertaining to e-cigarettes, confidence in advising
patients, and the content of patient advice provided.
Univariate analyses were primarily undertaken to achieve
these aims. The questionnaire included several open-
ended questions as described, which offered participants
the opportunity to enter free text. These brief free text re-
sponses were entered into a spreadsheet and coded; re-
sponses were coded initially by the primary coder (FS) and
the results were corroborated by a second coder (LN).
Further bivariate analyses were additionally undertaken to
explore differences between practitioner confidence in ad-
vising patients across socio-demographic and smoking-
related variables, using χ2 test or Fisher’s exact test as
appropriate for categorical variables. All statistical analyses
were performed using IBM SPSS Statistics for Windows
Version 21.0 (Armonk, NY).
Results
Most participants perceived e-cigarettes to be safer
than regular cigarettes (see Table 1) (n = 100, 68.5 %).
Participants who reported patient contact (n = 141,
96.6 %) were subsequently asked several questions per-
taining to patient e-cigarette use; the associated re-
sponses are detailed in Table 2. A large proportion of
practitioners had been asked about e-cigarettes by pa-
tients who were ever-smokers within the past year; only
18.7 % (n = 25) of practitioners reported no patients
having asked about e-cigarettes within the past year,
whilst, a small number reported more than three quar-
ters of patients having asked about e-cigarettes within
the past year (n = 4, 3.0 %). E-cigarette ever-use also
appeared to be prevalent in consideration of practi-
tioner responses, as almost half reported ever-use of e-
cigarettes among 25 % of more of their ever-smoking
patients (n = 62, 42.4 %), whilst a small number reported
none of their patients ever having used e-cigarettes (n = 6,
4.6 %). Similarly, regular e-cigarette use appeared prevalent
among patients; approximately a third of practitioners esti-
mated regular use of e-cigarettes among 25 % or more of
the ever-smoking patients they had seen in the past year
(n = 42, 32.6 %).
BTOG members with patient contact (n = 141) were
asked further questions regarding sources of e-cigarette
guidance and advice they provided to patients (see
Table 3). The results demonstrated that the majority of
participants were not aware of the IASLC statement per-
taining to e-cigarette use among cancer patients (n = 97,
72.4 %) and furthermore, most reported a lack of work-
place recommendations regarding e-cigarette use among
cancer patients (n = 122, 91.0 %). Participants additionally
reported poor levels of confidence regarding providing pa-
tients with e-cigarette-related advice. The vast majority of
participants agreed or strongly agreed that they needed
more information and guidance regarding e-cigarettes to
advise patients (n = 124, 92.6 %), whilst only a small pro-
portion of participants felt confident advising patients
regarding e-cigarettes (n = 28, 21.0 %).
The results also demonstrated inconsistencies regard-
ing the content of the advice provided to patients by
practitioners (Table 3). Most frequently, practitioners
advised that e-cigarettes were likely to be less harmful
that regular cigarettes (n = 45, 23.7 %) and that there is
a paucity of research and uncertainty regarding adverse
effects associated with e-cigarette use (n = 41, 21.6 %).
Table 2 Practitioners’ responses to questions regarding e-cigarette
use among patients with thoracic malignancies
Variable Participants n (%)
Proportion of ever-smoker patients who have:
Asked questions regarding e-cigarettesa
None 25 (18.7)
Less than a quarter 69 (51.5)
From a quarter to half 25 (18.7)
From a half to three quarters 11 (8.2)
More than three quarters 4 (3.0)
Ever-used e-cigarettesa
None 6 (4.6)
Less than a quarter 63 (48.1)
From a quarter to half 47 (35.9)
From a half to three quarters 12 (9.2)
More than three quarters 3 (2.3)
Regularly use e-cigarettesa
None 8 (6.2)
Less than a quarter 79 (61.2)
From a quarter to half 38 (29.5)
From a half to three quarters 3 (2.3)
More than three quarters 1 (0.8)
aFigures do not equate to 141 due to some missing data
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Some practitioners provided no advice or suggested
that they had inadequate knowledge to advise patients
(n = 12, 6.3 %). Furthermore, some explicitly described
how they would encourage (n = 7, 3.7 %) or conversely,
discourage patient e-cigarette use (n = 11, 5.8 %).
Bivariate associations between practitioner confidence
in advising patients regarding e-cigarettes and several
participant characteristics were examined. Practitioner
confidence in advising patients was found to differenti-
ate significantly by employment speciality (p = 0.030).
Nurses were most likely to disagree that they felt
confident advising patients (n = 33, 50.0 %), whilst those
who reported their employment speciality as respiratory
were most likely to agree that they felt confident advis-
ing patients (n = 10, 35.7 %). Male practitioners were
more likely to exhibit confidence in advising patients,
compared to females (p = 0.012) (see Table 4). Practi-
tioner confidence in advising patients was not found to
be significantly related to age, smoking status or e-
cigarette status.
Discussion
This is the first study, to our knowledge, to: (1) esti-
mate e-cigarette prevalence among patients with lung
cancer in Great Britain, and; (2) explore practice associ-
ated with e-cigarette use among cancer patients. These
components are important to investigate, as the associ-
ated findings contribute towards the development of
future research and guidance, as well as informing fu-
ture training delivered to practitioners working with
cancer patients who smoke.
There were a number of key findings in the current
study. The current study highlighted that the vast majority
of practitioners are being asked by their patients (those di-
agnosed with lung cancer) about e-cigarettes. Further-
more, the majority of practitioners frequently observed e-
cigarette ever-use among patients. Use of e-cigarettes in
the USA among patients with lung cancer was recently es-
timated to be 24 %; [7] the current results appear to reflect
these statistics, as observed patient use of e-cigarettes was
most often estimated to be below 25 %. The findings not
only ascertain frequent e-cigarette use among patients but
they demonstrate how a substantial proportion of patients
view practitioners as a source of advice and guidance re-
garding e-cigarettes and smoking cessation.
Despite prevalent use and frequent patient queries per-
taining to e-cigarettes, the survey revealed typically poor
levels of practitioner confidence regarding advising patients
on e-cigarettes. The results demonstrated how practitioner
confidence also differentiated by employment speciality
and gender, suggesting that specific groups could bene-
fit from further training and support in advising pa-
tients. Poor confidence was also reflected by the lack of
awareness of the aforementioned IASLC statement and
limited workplace recommendations pertaining to e-
cigarette use among cancer patients.
Table 3 Practitioners’ responses to questions regarding sources
of e-cigarette guidance and reported advice provided
Variable Participants n (%)
Awareness of IASLC statement regarding e-cigarette
use among cancer patientsa
Yes 37 (27.6)
No 97 (72.4)
Workplace recommended advice that practitioners should provide
regarding e-cigarettesa
Yes 12 (9.0)
No 122 (91.0)
“I feel I need more information and guidance
regarding electronic cigarettes”a
Strongly agree 53 (39.6)
Agree 71 (53.0)
Neutral 4 (3.0)
Disagree 6 (4.5)
Strongly disagree 0 (0.0)
“I feel confident advising patients regarding
electronic cigarettes” a
Strongly agree 4 (3.0)
Agree 24 (18.0)
Neutral 39 (29.3)
Disagree 49 (36.8)
Strongly disagree 17 (12.8)
Advice given to patients regarding e-cigarettesb
E-cigarettes are less harmful than regular
cigarettes
45 (23.7)
Paucity of research and uncertainty regarding
adverse effects
41 (21.6)
Patients should avoid using regular or electronic
cigarettes altogether
25 (13.2)
E-cigarettes may be an effective tool for smoking
cessation
20 (10.5)
E-cigarette use is discouraged 11 (5.8)
Seek support via Stop Smoking Services 10 (5.3)
Lack of regulation and caution regarding quality
control
10 (5.3)
No advice provided 9 (4.7)
E-cigarette use is encouraged 7 (3.7)
Consider the use of licenced smoking cessation
treatments primarily
5 (2.6)
E-cigarettes may be harmful to health 3 (1.6)
Inadequate knowledge to advise 3 (1.6)
No clear guidelines from professional bodies 1 (0.5)
aFigures do not equate to 141 due to some missing data, bMore than one
answer could be provided
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Extensive variability was additionally evident across
practitioner advice, with several conflicting examples of
practitioner advice being identified. Furthermore, prac-
titioners appeared substantially more optimistic regard-
ing e-cigarette harm compared with the general public;
69 % of practitioners in the current study perceived e-
cigarettes to be less harmful than regular cigarettes,
whilst only 52 % of the British general population were
recently estimated to perceive e-cigarettes as less harm
than regular cigarettes [23].
Prior research suggests that cancer patients perceive
practitioner advice regarding quitting as a key reason for
smoking cessation [24], whilst practitioner support has
been associated with smoking cessation success [25]. Prac-
titioners have, however, been found to exhibit personal be-
liefs regarding practice, which can conflict with evidence-
based guidance and ultimately impact practice [26–28].
The current results suggest that due to the absence of
evidence-based e-cigarette guidance or potentially, lack of
training, practitioners could be projecting their personal
beliefs regarding e-cigarette use onto patients. Inconsist-
ent practice is of great concern, as this could ultimately
affect patient outcomes. Although research continues to
aim to ascertain the safety and efficacy of e-cigarettes, the
reported low levels of practitioner confidence identified in
the current study, might be improved by increasing e-
cigarette-related training among practitioners and increas-
ing awareness of sources of e-cigarette guidance for both
practitioners and cancer patients.
The current study has a number of limitations.
Firstly, objective data were not available regarding pa-
tient e-cigarette use. Although the current study pro-
vides an estimate of e-cigarette use among patients with
lung cancer, some patients may not have accurately con-
veyed e-cigarette use to practitioners, which could have
resulted in an underestimation of patient use.
Secondly, there was a limited response rate from
BTOG members compared to some other surveys of
thoracic oncology providers [29] and therefore, data
analysis options were limited and the sample may not
have been fully representative of BTOG membership. This
may have been due to a lack of perceived e-cigarette im-
portance or clinical time constraints. It should be noted
that the study design entailed a self-selected sample and
findings could therefore result in potential bias, however,
this is a limitation of any self-selecting online survey [30].
Table 4 Associations between practitioner confidence advising patients regarding electronic cigarettes and demographic and
smoking-related variables
Variable Confident advising patients regarding e-cigarettes
Agree n (%) Neutral n (%) Disagree n (%) p-value
Agea 0.651
18-29 years 0 (0) 1 (2.6) 2 (3.0)
30-49 years 16 (57.1) 26 (66.7) 41 (62.1)
50-69 years 12 (42.9) 10 (25.6) 41 (62.1)
70 years and above 0 (0) 2 (5.1) 1 (1.5)
Gendera 0.012*
Male 17 (60.7) 13 (33.3) 19 (28.8)
Female 11 (39.3) 26 (66.7) 47 (71.2)
Employment specialitya 0.030*
Nursing 5 (17.9) 12 (30.8) 33 (50.0)
Respiratory 10 (35.7) 9 (23.1) 12 (18.2)
Clinical Oncology 9 (32.1) 7 (17.9) 7 (10.6)
Medical Oncology 1 (3.6) 5 (12.8) 5 (7.6)
Surgery 3 (10.7) 2 (5.1) 4 (6.1)
Other 0 (0) 4 (10.3) 5 (7.6)
Smoking statusa 0.969
Never 8 (28.6) 11 (28.2) 20 (30.3)
Ever 20 (71.4) 28 (71.8) 46 (69.7)
E-cigarette statusa 0.633
Never 3 (10.7) 3 (7.7) 4 (6.1)
Ever 25 (89.3) 36 (92.3) 62 (93.9)
aFigures do not equate to 141 due to some missing data, * p < 0.05
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A larger survey or qualitative study may now be helpful to
verify these findings and to explore strategies designed to
improve practitioners’ knowledge and confidence regard-
ing advising patients about e-cigarettes.
This study highlights the extreme disparities between
practitioners in relation to the guidance provided and also
suggests that current guidance is either not being accessed
or is being ignored. The disparity that exists among practi-
tioners warrants further consideration. The MHRA in-
tends to regulate e-cigarettes in May 2016 [10], which
should improve attempts to ascertain product safety and
efficacy. Whilst further research explores the efficacy and
safety of e-cigarettes in this context, efforts should be
made to ensure regular training and support for practi-
tioners regarding e-cigarette use among cancer patients,
particularly across employment specialities that demon-
strate low confidence in advising patients (e.g., nursing);
in doing so, practitioner competence and confidence
advising patients regarding e-cigarettes should increase,
which could improve smoking cessation rates and in
turn, patient outcomes. Furthermore, guidance regard-
ing e-cigarette use among cancer patients should be up-
dated regularly, in line with the rapidly evolving e-
cigarettes evidence-base; this will promote the provision
of up-to-date and accurate e-cigarette practitioner advice.
Conclusion
This is the first study, to our knowledge, that attempts
to estimate e-cigarette prevalence among cancer pa-
tients in Great Britain and explores practice associated
with e-cigarette use among cancer patients. The study
revealed the prevalence of both e-cigarette use and
associated patient-practitioner queries. Although the
results highlighted that patients rely upon practitioners
as a source of guidance regarding e-cigarettes, practi-
tioners typically demonstrated low levels of confidence
in guiding patients and poor awareness of sources of
guidance pertaining to e-cigarette use among cancer
patients. The findings have important implications for
practitioner training, as well as future research and pol-
icy. Effective and consistent practitioner advice regard-
ing e-cigarettes and smoking cessation could improve
smoking cessation rates and subsequently, improve pa-
tient outcomes.
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